FindTrial
Sign In

Post hoc analysis of the SIRFLOX study: radiomics analysis of baseline CT images with the intention to identify predictors of superior response and overall survival to a combined treatment approach (SIRT plus chemotherapy) as compared to chemotherapy alone

Post hoc analysis of the SIRFLOX study: radiomics analysis of baseline CT images with the intention to identify predictors of superior response and overall survival to a combined treatment approach (SIRT plus chemotherapy) as compared to chemotherapy alone

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00034673
Enrollment
530
Registered
2024-09-23
Start date
2024-09-16
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.7 C20 C18.9

Interventions

Group 1: Feature extraction will be performed from all baseline CT scans of the SIRFLOX study (both treatment arms), focusing primarily on liver metastases. Feature extraction includes optimization o

Sponsors

Klinik und Poliklinik für Radiologie; LMU Klinikum
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients treated in the SIRFLOX study

Exclusion criteria

Exclusion criteria: Baseline CT not available

Design outcomes

Primary

MeasureTime frame
Overall survival (OS) based on existing patient data from treatment to death.—

Secondary

MeasureTime frame
- Progression-Free Survival (PFS) - Liver-specific progression-free survival (hepatic progression-free survival, hPFS)—

Countries

Germany

Contacts

Public ContactMax Seidensticker

Klinik und Poliklinik für Radiologie; LMU Klinikum

Max.Seidensticker@med.uni-muenchen.de+49 89 4400 73620

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026